Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1021-1028

  Bansard, Carine ^a   Lequerré, Thierry ^a,b,c   Daveau, Maryvonne ^a,c   Boyer, Olivier ^a   Tron, Francois ^a,c   Salier, Jean Philippe ^a,c   Vittecoq, Olivier ^a,b,c   Le Loët, Xavier ^a,b,c  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Rouen University Hospital ^*  (France)

Author keywords

Biologics; Biomarkers predictive of response; Methotrexate; Pharmacogenetics; Pharmacogenomics; Rheumatoid arthritis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 AMINOIMIDAZOLE 4 CARBOXAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; ADALIMUMAB; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE 1; BIOLOGICAL MARKER; CALGRANULIN A; CALPASTATIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FC RECEPTOR IIA; FC RECEPTOR IIB; FIBRINOGEN; HEAT SHOCK PROTEIN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEOGLYCAN; THYMIDYLASE SYNTHASE; TRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR;

CLINICAL FEATURE; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HETEROZYGOTE; HIGH THROUGHPUT SCREENING; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; TREATMENT RESPONSE; BLOOD; DRUG COMBINATION; GENETICS; PROGNOSIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; METHOTREXATE; PHARMACOGENETICS; PROGNOSIS; TREATMENT OUTCOME;

EID: 70349784825     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep112     Document Type: Review

References (77)

1. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
2. Le Loët X, Berthelot JM, Cantagrel A et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45-50.
3. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
5. Zink A, Strangfeld A, Schneider M et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407.
6. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
7. Bridges SL Jr. The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response. Curr Rheumatol Rep 1999;1:164-71.
8. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30:2315-8.
9. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
10. Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2005;6:481-90.
11. Bridges SL Jr. Genetic markers of treatment response in rheumatoid arthritis. Arthritis Rheum 2004;50:1019-22.
12. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 2003;4:187-96.
13. van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003;48: 2132-45.
14. Batliwalla FM, Baechler EC, Xiao X et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005;6:388-97.
15. Devauchelle V, Marion S, Cagnard N et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun 2004;5:597-608.
16. Olsen N, Sokka T, Seehorn C et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 2004;63:1387-92.
17. Jarvis JN. Diagnostic and prognostic potential of gene microarrays in rheumatoid arthritis. Expert Rev Mol Diagn 2005;5:655-9.
18. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1: 683-95.
19. Hueber W, Utz PJ, Steinman L, Robinson WH. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 2002;4:290-5.
20. Machour N, Gilbert D, Vittecoq O, Costa O, Tron F, Charlionet R. Proteomics and autoantibody. Med Sci 2005;21:759-64.
21. Bologna C, Viu P, Jorgensen C, Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996;35:453-7.
22. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
23. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
24. Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB, van Riel PL. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8.
25. Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons D. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 2008;68:57-62.
26. Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW. Genetic markers of treatment response in rheumatoid arthritis. Curr Rheumatol Rep 2006;8:369-77.
27. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
28. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
29. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy and toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 2006;124:521-6.
30. Ghodke Y, Chopra A, Joshi K, Patwardhan B. Are thymidylate synthase and methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? Clin Rheumatol 2008;27:787-9.
31. Dervieux T, Lein DO, Park G, Barham R, Smith K, Walsh M. Single nucleotide polymorphisms (SNPs) in the folate/purine synthesis pathway predict methotrexate's effects in rhematoid arthritis. Arthritis Rheum 2003;48(Suppl. 9):S438.
32. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:496-503.
33. Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006;24:546-4.
34. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
35. Wessels JA, Kooloos WM, de Jonge R et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.
36. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
37. Tolusso B, Pietrapertosa D, Morelli A et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006;7:683-95.
38. Ali AA, Moatter T, Baig JA, Iqbal A, Hussain A, Iqbal MP. Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate - a hospital-based study. J Pak Med Assoc 2006;56:452-6.
39. Alessandri C, Bombardieri M, Papa N et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-1.
40. Bobbio-Pallavicini F, Caporali R, Alpini C et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.
41. Braun-Moscovici Y, Markovits D, Zinder O et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:497-500.
42. Buch MH, Seto Y, Bingham SJ et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52: 42-8.
43. Wolbink GJ, Voskuyl AE, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:704-7.
44. Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007;26:1335-8.
45. Lequerré T, Jouen F, Brazier M et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology 2007;46:446-53.
46. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
47. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005;7:R149-55.
48. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008;58:1258-63.
49. Pachot A, Arnaud B, Marrote H et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 2007;34:2158-61.
50. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48: 1849-52.
51. Fonseca JE, Carvalho T, Cruz M et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005;64:793-4.
52. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007;46:93-6.
53. Guis S, Balandraud N, Bouvenot J et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007;57:1426-30.
54. Martinez A, Salido M, Bonilla G et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82.
55. Marotte H, Pallot-Prades B, Grange L et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006;65:342-7.
56. Cuchacovich M, Ferreira L, Aliste M et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004; 33:228-32.
57. Padyukov L, Lampa J, Heimburger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
58. Criswell LA, Lum RF, Turner KN et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6.
59. Miceli-Richard C, Comets E, Verstuyft C et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008;67:478-4.
60. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005;44:547-52.
61. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002;29:1847-50.
62. Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun 2005;6:467-71.
63. Nepom GT, Byers P, Seyfried C et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 1989;32:15-21.
64. Kastbom A, Bratt J, Ernestam S et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448-52.
65. Miceli-Richard C, Ohresser M, Comets E et al. Analyse des polymorphismes des gènes des récepteurs FcgIIA, -IIIB et -IIIB comme facteurs prédictifs de la réponse à l'adalimumab (Etude ReAct) au cours de la polyarthrite rhumatoïde. Rev Rhum [Ed Fr] 2006;73:1094.
66. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693-6.
67. Liu C, Batliwalla F, Li W et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-81.
68. Lequerré T, Gauthier-Jauneau AC, Bansard C et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006;8:R105-15.
69. Bansard C, Lequerré T, Hiron M et al. Identification de marqueurs prédictifs de réponse à l'anakinra chez des patients atteints de polyarthrite rhumatoïde. Rev Rhum [Ed Fr] 2007;74:1021.
70. Toonen EJ, Barrera P, Radstake TR et al. Gene expression profiling in rheumatoid arthritis; current concepts and future directions. Ann Rheum Dis 2008;67:1663-1669.
71. Koczan D, Drynda S, Hecker M et al. Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008;10:R50-9.
72. Lindberg J, Klint E, Catrina AI et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006;8:R179-90.
73. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008;67:563-6.
74. Gobezie R, Millett PJ, Sarracino DS, Evans C, Thornhill TS. Proteomics: applications to the study of rheumatoid arthritis and osteoarthritis. J Am Acad Orthop Surg 2006;14:325-32.
75. Trocmé C, Marotte H, Baillet A et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis. Advance Access published July 29, 2008, doi:10.1136/ard.2008.093153.
76. Drynda S, Ringel B, Kekow M et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract 2004;200:165-71.
77. Hueber W, Batliwalla F, Tibshirani R et al. Proteomic signatures of secreted proteins for the prediction of treatment response to TNF blockers in RA. Clin Immunol 2007;123:S94.